Highlights in HER2-low breast cancer at SABCS 2022

What is HER2 low in breast cancer?Подробнее

Novel antibody-drug conjugates (ADCs) technologies for management of mBCПодробнее

Remaining questions surrounding HER2-low breast cancer – how low can you go?Подробнее

SABCS 2022: key highlightsПодробнее

Ask The Expert: SABCS HighlightsПодробнее

Key data at SABCS 2022Подробнее

HER2+ SABCS 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Erika HamiltonПодробнее

SABCS 2022: clinical trial highlightsПодробнее

HR+ SABCS 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Stephanie GraffПодробнее

CDK4/6i in HR+ SABCS 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Sara TolaneyПодробнее

Hall A Key Highlights from SABCS 12 Feb2022Подробнее

Key takeaways from SABCS 2022Подробнее

San Antonio Breast Cancer Symposium 2022 highlightsПодробнее

The evolution of HER2-low breast cancer from primary to recurrenceПодробнее

Discussion highlights from SABCS 2022Подробнее

Key highlights from SABCS 2022Подробнее

Hall A - Key Highlights from SABCS - 12 Feb2022Подробнее

SABCS 2022 highlightsПодробнее

Highlights from the San Antonio Breast Cancer Symposium 2022Подробнее